Exogenous oestrogen (administered as HRT) reduces breast cancer rates

While endogenous oestrogen (i.e., oestrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing oestrogen alone (the exogenous oestrogen) provides a protective effect in reducing breast cancer risk, according to study results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, Dec 8-12.

“Our analysis suggests that, contrary to previous thinking, there is substantial value in bringing HRT with oestrogen alone to the guidelines. The data show that for selected women it is not only safe, but potentially beneficial for breast cancer, as well as for many other aspects of women’s health,” said lead researcher Joseph Ragaz, M.D., medical oncologist and clinical professor in the faculty of medicine, School of Population and Public Health at The University of British Columbia, Vancouver, BC, Canada.

“These findings should intensify new research into its role as a protective agent against breast cancer,” he added.

Ragaz and colleagues reviewed and reanalyzed data from the Women’s Health Initiative (WHI) hormone replacement therapy trials. WHI is a national health study that focuses on strategies for preventing heart disease, breast and colorectal cancer, and fracture in postmenopausal women. The WHI was launched in 1991 and includes more than 161,000 U.S. women aged 50 to 79 years.

“Over the last 30 years HRT has been used almost indiscriminately by women expecting the benefit of reducing cardiac risks, while providing a protective effect against bone fracture, and improving overall quality of life,” said Ragaz. “The WHI results as originally interpreted led to a major pendulum swing against HRT.”

The WHI HRT trial consisted of two cohorts of women; the oestrogen-alone group of women without a uterus and the oestrogen-plus-progestin group of women with a uterus.

Ragaz and colleagues reanalyzed the WHI studies in more detail and found that subsets of women with no strong family history of breast cancer who received oestrogen alone had a significantly reduced breast cancer incidence. In addition, the 75 percent of women without benign disease prior to the trial enrollment also had a reduced breast cancer risk.

“Reduction of rates of breast cancer in the majority of women who are candidates for oestrogen-based HRT is a new finding because oestrogen was always linked with a higher incidence of breast cancer,” Ragaz said, “yet oestrogen administered exogenously is actually protective for most women.”
Based on the results of this current analysis, Ragaz suggested that “while the use of HRT with oestrogen alone may reduce the risk of breast cancer and may also be appropriate to manage menopausal symptoms, further research is warranted to elaborate on the optimum treatment regimen, to refine the selection of ideal candidates for oestrogen therapy, and to understand the oestrogen mechanisms that support the prevention of human breast cancer.”
“The recommendations based on prior analyses of the results of the WHI HRT studies was not to use HRT, but we are optimistic this will change,” he said. “Our conclusion, based on the data presented, should enhance considerations for an early approval of HRT based on oestrogen-alone for the majority of selected women suffering with menopausal symptoms and galvanize new research on HRT to define the optimum regimens for individual women.”